Recent news on Ethyol

Response Rate to Chemotherapy for NSCLC not Affected by Ethyol®  -  May 2, 2007
Cancer Consultants (press release),Ethyol® is a radiation protector and the only drug that has been approved by the FDA for this use in patients receiving radiation therapy for cancers of the

FDA panel approves FluMist for kids under 5  -  May 17, 2007
The Money Times,Besides FluMist, its nasal spray flu vaccine, also on the market are Ethyol, which treats side effects of chemotherapy and radiation; and Neutrexin,

MedImmune profits triple in first quarter  -  May 1, 2007
Bizjournals.com,Blockbuster Synagis grew 9 percent to $506.8 million in sales, and Ethyol grew 14 percent to nearly $23 million in sales -- in part due to their higher

AstraZeneca snaps MedImmune for $15.6bn  -  Apr 25, 2007
DrugResearcher.com,...and has two other marketed products, Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy-related side effects.

AstraZeneca to buy MedImmune for $15 billion  -  Apr 23, 2007
Reuters...but it also has two other marketed products, Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy side effects.

AstraZeneca Buys MedImmune For $15.6 Billion  -  Apr 23, 2007
Playfuls.com,...buy acquiring MedImmune’s FluMist influenza treatment, Synagis for infant respiratory infections, and Ethyol for reducing chemotherapy side effects.

£7.6bn US biotech buy boosts AstraZeneca  -  Apr 23, 2007
This is Money,MedImmune, best-known for nasal spray flu vaccine FluMist, also markets Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy

Maryland biotech firm up for sale  -  Apr 12, 2007
Washington Times,MedImmune also manufactures Ethyol for reducing chemotherapy side effects. The once-promising nasal spray flu vaccine FluMist, introduced four years ago,

EXCLUSIVE-MedImmune Hires Goldman to Explore Sale  -  Apr 12, 2007
Reuters.uk,...nasal spray flu vaccine FluMist but it also has two other marketed products -- respiratory drug Synagis and Ethyol for reducing chemotherapy toxicities.

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion  -  Apr 23, 2007
BioWorld Online,Revenues for Ethyol, a product to reduce dry mouth in patients undergoing chemotherapy or radiation therapy, were $87 million. And revenues for FluMist,

WALL STREET OUTLOOK Lower as investors  -  Apr 23, 2007
Hemscott,MedImmune is best known Synagis, a treatment for respiratory infections and Ethyol, a drug used to minimise the side-effects of certain cancer chemotherapy

AstraZeneca confirms to acquire MedImmune for US$15.6bn  -  Apr 23, 2007
The Money Times,Numax, next generation follow-on to Synagis and Ethyol for reducing chemotherapy side effects are also included in the pipeline.

Ethyol® Can Be Administered Subcutaneously to Prevent Xerostomia  -  Feb 5, 2007
Cancer Consultants (press release),According to an article recently published in the International Journal of Radiation, Oncology, Biology and Physics, Ethyol® (amifostine) can be

Ethyol® Can Be Administered Subcutaneously to Prevent Radiation ...  -  Feb 2, 2007
Cancer Consultants (press release),A phase II multicenter trial has demonstrated that Ethyol (amifostine) can be administered subcutaneously for the prevention of radiation induced xerostomia

MedImmune Q4 2006 Earnings Call Transcript  -  Feb 7, 2007
Seeking Alpha,Ethyol sales for 2006 came in at $87 million as compared to $95 million in 2005. For the fourth quarter of 2006 sales totaled $20 million as compared to $25

Analysis: Mixed reviews on MedImmune  -  Feb 7, 2007
Science Daily (press release)In addition to Synagis and FluMist missing the mark, he noted revenues from the company's other products, including Ethyol, its HPV franchise and government

MedImmune Reports Financial Results For 2006  -  Feb 7, 2007
PR Newswire (press release),Sales of Ethyol were $20 million in the 2006 fourth quarter and $87 million for the year, while sales of the product were $25 million in the fourth quarter

MedImmune: Lawsuit Developments Mixed  -  18 Jan 2007
Forbes,MedImmune sued in August 2004 over Sun's proposed generic version of amifostine, the active ingredient in Ethyol. Ethyol treats dry mouth in cancer patients

MedImmune Announces District Court's Rejection of Sun ...  -  Jan 14, 2007
Drug Newswire (press release),MedImmune Oncology is a subsidiary of MedImmune, through which the company manufactures Ethyol(R) (amifostine). To date, Ethyol accounts for all

MedImmune posts FDA, court wins  -  Jan 11, 2007
Business Gazette,On Wednesday, a federal district court in Maryland rejected Sun’s motion to drop MedImmune’s infringement suit on an Ethyol patent, but also ruled that Sun

MedImmune Ruling Opens Gates For Patent Challenges  -  Jan 12, 2007
Southern Maryland Online,MedImmune employs approximately 2500 people and markets three products Synagis, Ethyol (a cancer drug) and the influenza vaccine FluMist said Barrett.

Market Report -- In Play (MEDI)  -  Jan 10, 2007
MSN MoneyThe '731 and '471 patents cover Ethyol. "This decision means that MedImmune may continue its efforts of vigorously enforcing the '731 patent against Sun.'"

The Navicor Group Honored at 2006 Rx Club Awards  -  Dec 12, 2006
PharmaLive.com (press release),..."Ethyol campaign photography" for MedImmune's Ethyol in the graphics: photography category; and * "Ethyol advertorial" for MedImmune's Ethyol in the

MedImmune finalizes $50 million sale of CytoGam  -  Dec 19, 2006
Examiner.comEthyol is a therapeutic for cancer patients going through chemotherapy. The nasal flu vaccine, FluMist, is the first flu vaccine that combats the flu where

Ayurvedic mouthwash to relieve radiation pain in cancer patients  -  Dec 17, 2006
domain-B,The commonly used drug to control mucositis called Amifostine (Ethyol) costs approximately Rs9,000 per dose (single injection half an hour before radiation)

Mouthwash to help cancer treatment pain  -  Dec 15, 2006
Times of India,The commonly used drug to control mucositis is called Amifostine (Ethyol) that costs Rs 9000 per dose. It has to be injected half-an-hour before radiation.

Focus today mirrors MedImmune’s past  -  Dec 7, 2006
Business Gazette,MedImmune now has three products on the market: the nasal spray vaccine FluMist for influenza; Ethyol, to reduce toxic effects of chemo- and radiation

MedImmune expects growth to 2009  -  Dec 6, 2006
Monsters and Critics.com,...billion in revenues anticipated for this year included sales of Synagis, Ethyol and FluMist as well as royalties from the company`s human papillomavirus

MedImmune sells drug product for $50M  09 Nov 2006
...plasma and is used to treat infections from organ transplants, is the oldest of four products MedImmune had on the market, including Synagis, FluMist and Ethyol ... -Milwaukee Business Journal, Sun Pharma receives tentative approval for Amifostine  Oct 20, 2006
...cisplatin. Ethyol is currently covered under 3 patents-‘471 (July 31,2012), ‘731 (July 31,2012) and ‘409 (Dec 8,2017). Sun ... -Moneycontrol.com, Competitive Technologies and CCA Industries to Partner on New ...  Aug 30, 2006
Some of the more notable technologies CTT has brought to market include the gallium arsenide laser, vitamin B12, Ethyol(TM) (an agent that reduces certain side ... -Business Wire

The Navicor Group Honored at 2006 Rx Club Awards  -  12 Dec 2006
PharmaLive.com (press release),..."Ethyol campaign photography" for MedImmune's Ethyol in the graphics: photography category; and * "Ethyol advertorial" for MedImmune's Ethyol in the

Focus today mirrors MedImmune’s past  -  Dec 7, 2006
Business Gazette,MedImmune now has three products on the market: the nasal spray vaccine FluMist for influenza; Ethyol, to reduce toxic effects of chemo- and radiation

MedImmune expects growth to 2009  -  Dec 6, 2006
Monsters and Critics.com,...billion in revenues anticipated for this year included sales of Synagis, Ethyol and FluMist as well as royalties from the company`s human papillomavirus

Additional Evidence that Ethyol® Reduces Dry Mouth in Patients ...  Jul 31, 2006
Among patients receiving radiation therapy for advanced head and neck cancer, treatment with Ethyol® (amifostine) either three times per week or five times ... -Cancer Consultants

L-Glutamine Effective for Prevention of Oral Musositis After ...  Aug 7, 2006
...approaches have been used to decrease the incidence and severity of mucositis, including local cryotherapy, the administration of Ethyol (amifostine), and the ... -Cancer Consultants

Indication for Ethyol® Withdrawn  Jun 30, 2006
MedImmune has voluntarily withdrawn an indication for their agent Ethyol (amifostine) after talks with the Food and Drug Administration (FDA). ... -Cancer Consultants

MedImmune, Inc. Q2 2006 Earnings Conference Call Transcript (MEDI)  Jul 20, 2006
...second quarter were $73 million, of which $66 million was from product sales including $33 million from worldwide sales of Synagis and $25 million from Ethyol. ... -Seeking Alpha

Weak Showing at Medimmune  Jul 20, 2006
...of $66 million, including $33 million in worldwide sales of respiratory virus drug Synagis and $25 million in sales of cancer treatment side effect drug Ethyol ... -TheStreet.com



MedImmune Hurt by Synagis Sales  Apr 20, 2006
First-quarter sales of the ovarian cancer drug Ethyol were $20 million, compared to $23 million last year, mainly because of competition from other cancer ... - TheStreet.com

MedImmune profit slips, shares drop  Apr 20, 2006
Worldwide sales of Ethyol -- designed to reduce side effects associated with certain cancer chemotherapy and radiotherapy -- were $20 million in the first ... - MarketWatch

MedImmune Reports Financial Results for First Quarter 2006  Apr 20, 2006
Worldwide sales of Ethyol® (amifostine) were $20 million in the 2006 first quarter compared to $23 million in the first quarter last year. ... - Yahoo! News



Drug Improves Radiation Side Effects  Mar 1, 2006
...(Ivanhoe Newswire) -- A new study reveals the drug amifostine (Ethyol) may ease common side effects associated with radiation therapy while making the cancer ... - Ivanhoe,

MedImmune Swings to a Loss  Feb 2, 2006
The others are the nasal spray flu vaccine, FluMist, which had $21 million in sales last year, and Ethyol, a treatment for certain side effects caused by ... - TheStreet.com

MedImmune Reports 2005 Financial Results  Feb 2, 2006
4Q2004 Total Product Sales $1,221 9% $482 5% Synagis - Total 1,063 13 439 9 Synagis - US 905 9 379 5 Synagis - ROW 158 45 60 43 Ethyol(R) (amifostine) 95 3 25 ... - PR Newswire,

MedImmune Swings to a Loss  Feb 2, 2006
The others are the nasal spray flu vaccine, FluMist, which had $21 million in sales last year, and Ethyol, a treatment for certain side effects caused by ... - TheStreet.com

MedImmune slides on weak earnings  Feb 2, 2006
Its chemotherapy aid Ethyol saw sales rise 16% to $25 million. Sales of the company's flu vaccine, FluMist, dropped 61% to $8 million. ... - MarketWatch

MedImmune Reports 2005 Financial Results  Feb 2, 2006
4Q2004 Total Product Sales $1,221 9% $482 5% Synagis - Total 1,063 13 439 9 Synagis - US 905 9 379 5 Synagis - ROW 158 45 60 43 Ethyol(R) (amifostine) 95 3 25 ... - PR Newswire

MedImmune posts 4Q loss  Feb 2, 2006
...mark worldwide for the first time. Sales of the cancer patient drug Ethyol were also higher. For 2006, MedImmune forecast between ... - Baltimore Sun

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional